GlassScriptPhysician profile
Malshundria Prophet
NPI 1073658332
$7,937.28
in general payments reported to CMS, 2019-2025
59 companies · $1,900 in 2025
The $1,900 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $352 · 2021: $737 · 2022: $985 · 2023: $1,682 · 2024: $2,171 · 2025: $1,900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,476 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,476.07 |
| Education | $276.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $559.34 | 2021-2025 | |
| Janssen Biotech, INC. | $448.54 | 2023-2025 | Darzalex, Tecvayli, Carvykti |
| Merck Sharp & Dohme LLC | $445.49 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $434.60 | 2022-2025 | |
| Astellas Pharma US INC | $421.88 | 2022-2025 | Xtandi, Xospata, Padcev |
| Pfizer INC. | $396.37 | 2023-2025 | |
| Daiichi Sankyo INC. | $377.20 | 2020-2025 | Injectafer, Enhertu |
| Astrazeneca Pharmaceuticals LP | $316.91 | 2022-2025 | Calquence, Tagrisso, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $277.36 | 2022-2025 | Opdivo, Opdualag, Krazati |
| Amgen INC. | $234.13 | 2020-2023 | Kyprolis |
| Eusa Pharma (US) LLC | $230.93 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $209.69 | 2022-2025 | Alunbrig, Fruzaqla, Iclusig |
| Secura Bio, INC. | $185.40 | 2021-2022 | |
| Celgene Corporation | $167.54 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| Exelixis INC. | $166.00 | 2022-2025 | Cabometyx |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $165.47 | 2022-2025 | Monjuvi, Jakafi, Zynyz |
| Janssen Pharmaceuticals, INC | $164.17 | 2020-2024 | Xarelto |
| Sobi, INC | $159.61 | 2024-2025 | |
| Eagle Pharmaceuticals, INC. | $154.99 | 2024 | |
| Genentech USA, INC. | $150.62 | 2023-2025 | Venclexta, Lunsumio, Polivy |
| Alexion Pharmaceuticals, INC. | $144.05 | 2019-2024 | Ultomiris |
| Lilly USA, LLC | $140.42 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Seagen INC. | $134.27 | 2021-2023 | Tukysa, Adcetris |
| Array Biopharma INC | $132.00 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Abbvie INC. | $127.10 | 2024-2025 | |
| Genmab U.S., INC. | $118.50 | 2022-2025 | Tivdak, Epkinly |
| Glaxosmithkline, LLC. | $104.84 | 2024-2025 | Ojjaara, Blenrep |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Gilead Sciences, INC. | $96.15 | 2023-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $92.34 | 2022-2025 | Libtayo |
| Deciphera Pharmaceuticals INC. | $89.92 | 2023-2024 | Qinlock |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.50 | 2024-2025 | Gilotrif |
| Puma Biotechnology, INC. | $79.19 | 2022-2025 | |
| Eisai INC. | $75.58 | 2023-2024 | |
| Rigel Pharmaceuticals, INC. | $69.06 | 2023-2024 | Rezlidhia, Tavalisse |
| Mirati Therapeutics, INC. | $56.45 | 2023-2024 | Krazati |
| Adc Therapeutics America, INC. | $54.53 | 2022-2024 | |
| Macrogenics, INC. | $47.42 | 2022-2023 | |
| Spectrum Pharmaceuticals INC. | $47.04 | 2023-2025 | Rolvedon |
| Immunocore Limited | $44.85 | 2024-2025 | Kimmtrak |
| Jazz Pharmaceuticals INC. | $44.76 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $44.54 | 2022-2024 | Xpovio |
| Taiho Oncology, INC. | $40.43 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.90 | 2022-2023 | |
| Aveo Pharmaceuticals, INC. | $24.57 | 2024 | |
| Tersera Therapeutics LLC | $24.14 | 2025 | Zoladex |
| Geron Corporation | $23.62 | 2025 | Rytelo |
| Ipsen Biopharmaceuticals, INC | $23.09 | 2022 | |
| Verastem, INC. | $19.77 | 2025 | Avmapki Fakzynja Co-Pack |
| Stemline Therapeutics INC. | $19.66 | 2025 | Orserdu |
| Kyowa Kirin, INC. | $18.03 | 2024 | Poteligeo |
| Emd Serono, INC. | $17.96 | 2025 | |
| Sumitomo Pharma America, INC. | $17.84 | 2023 | Orgovyx |
| G1 Therapeutics, INC. | $17.12 | 2023 | Cosela |
| Beigene USA, INC. | $14.79 | 2023 | Brukinsa |
| Springworks Therapeutics, INC. | $14.18 | 2024 | Ogsiveo |
| Morphosys, US INC. | $14.16 | 2023 | Monjuvi |
| Helsinn Therapeutics (U.S.), INC. | $13.68 | 2022 | |
| Blueprint Medicines Corporation | $13.64 | 2023 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malshundria Prophet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.